{"symbol":"MRK","provider":"yahoo-finance","fetchedAt":"2025-12-23T15:57:00.499Z","asOfDate":"2025-12-23","articles":[{"id":"8da82c68-9ff0-3427-9e31-bf8f3472e95b","title":"Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?","url":"https://finance.yahoo.com/news/wall-street-analysts-think-merck-143004805.html","publisher":"Zacks","publishedAt":"2025-12-23T14:30:04.000Z","relatedTickers":[],"mainIdea":"Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?","summary":"Zacks: Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?. Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?"},{"id":"69a3fc90-5c9a-3f39-ba20-b0a55ac4346e","title":"Dogs of the Dow Enhanced Income Strategy with Covered Calls","url":"https://finance.yahoo.com/m/69a3fc90-5c9a-3f39-ba20-b0a55ac4346e/dogs-of-the-dow-enhanced.html","publisher":"Barchart","publishedAt":"2025-12-23T12:00:02.000Z","relatedTickers":["^DJI"],"mainIdea":"Dogs of the Dow Enhanced Income Strategy with Covered Calls","summary":"Barchart: Dogs of the Dow Enhanced Income Strategy with Covered Calls. The Dogs of the Dow has long been a simple, rules-based approach to equity investing, built around owning the highest-yielding stocks in the Dow Jones Industrial Average. Each year, investors rotate into the 10 Dow components with the highest dividend yields, based on the assumption that these stocks are temporarily out of favor and may rebound over time. Related tickers mentioned: ^DJI."},{"id":"65a995e2-731e-3bd8-ac46-a5c62b2ff7d7","title":"SCHD vs. NOBL: Different Paths to Dividend Stability","url":"https://finance.yahoo.com/m/65a995e2-731e-3bd8-ac46-a5c62b2ff7d7/schd-vs.-nobl%3A-different.html","publisher":"Motley Fool","publishedAt":"2025-12-22T21:31:52.000Z","relatedTickers":["SCHD"],"mainIdea":"SCHD vs. NOBL: Different Paths to Dividend Stability","summary":"Motley Fool: SCHD vs. NOBL: Different Paths to Dividend Stability. Both ETFs target dividend paying stocks, but their rules determine whether investors receive higher income or stricter dividend consistency Related tickers mentioned: SCHD."},{"id":"13190dd5-50f6-360e-8931-02493ad33b77","title":"“Merck (MRK) is an Inexpensive Stock,” Says Jim Cramer","url":"https://finance.yahoo.com/news/merck-mrk-inexpensive-stock-says-172937950.html","publisher":"Insider Monkey","publishedAt":"2025-12-22T17:29:37.000Z","relatedTickers":[],"mainIdea":"“Merck (MRK) is an Inexpensive Stock,” Says Jim Cramer","summary":"Insider Monkey: “Merck (MRK) is an Inexpensive Stock,” Says Jim Cramer. We recently published 8 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radars. Pharma giant Merck & Co., Inc. (NYSE:MRK)’s shares are up by 1.9% year-to-date on the back of a strong run since early November. Before the run started, the stock was down 16.8% […]"},{"id":"619e667d-d82c-327c-b226-63865170214e","title":"Analyst Report: Merck & Co., Inc.","url":"https://finance.yahoo.com/m/619e667d-d82c-327c-b226-63865170214e/analyst-report%3A-merck-%26-co.%2C.html","publisher":"Morningstar Research","publishedAt":"2025-12-22T16:38:21.000Z","relatedTickers":[],"mainIdea":"Analyst Report: Merck & Co., Inc.","summary":"Morningstar Research: Analyst Report: Merck & Co., Inc.. Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines)."}]}
